Business Wire

Sony Music Foundation Presents "THE 12th INTERNATIONAL OBOE COMPETITION OF JAPAN 2018 in Tokyo"

Jaa

Sony Music Foundation will be hosting “THE 12th INTERNATIONAL OBOE COMPETITION OF JAPAN 2018 in Tokyo” in September and October next year. The Competition is being held triennially since 1985, and to date, the prize winners are very active and successful including having taken the position of the principal oboists of world famous orchestra.

The first seven competitions were held in Tokyo. The venue was changed to Karuizawa, Nagano for the next four competitions, the 11th competition being the most recent. The 12th competition will be held in Tokyo for nine days from September 29 through October 7, 2018.

Official website: http://oboec.jp/index_e

[Dates]  

Period for application:

February 15 (Thu) through March 13 (Tue), 2018 (must arrive by this date, Japan time)

Preliminary Screening with recorded materials (closed to the public): April, 2018

Registration:

September 26 (Wed), 2018

 
(Following rounds are all open to the public)

First Round:

September 29 (Sat), 30 (Sun), 2018 at Tokyo Opera City Recital Hall

Results announcement: September 30 (Sun)

Second Round:

October 2 (Tue), 3 (Wed), 4 (Thu), 2018 at Tokyo Opera City Recital Hall

Results announcement: October 4 (Thu)

Final Round and Award Presentation Ceremony: October 6 (Sat), 2018 at Kioi Hall

Prize Winners & Jury Concert:

October 7 (Sun), 2018 at Kioi Hall

 
[Place]
First and Second Rounds

Tokyo Opera City Recital Hall

https://www.operacity.jp/en/concert/index.php

Address: 3-20-2 Nishi-shinjuku, Shinjuku-ku, Tokyo, 163-1403 Japan
 
Final Round and Award Presentation Ceremony

Kioi Hall

http://www.kioi-hall.or.jp/en

Address: 6-5, Kioi-cho, Chiyoda-ku, Tokyo, 102-0094 Japan
 
[Jury Chairman]

Hansjorg SCHELLENBERGER

(Oboist, Conductor)
 

[Members of Jury] (in alphabetical order)

Maurice BOURGUE

(Oboist)

Ken-ichi FURUBE

(Principal Oboist - New Japan Philharmonic)

Gordon HUNT

(Principal Oboe - London Chamber Orchestra, former Principal Oboe - Philharmonia Orchestra, Conductor)

Yoshiaki OBATA

(Professor at Tokyo University of the Arts)

Dwight PARRY

(Principal Oboist - Cincinnati Symphony Orchestra)

Masaru YOSHIDA

(Principal Bassoonist - Yomiuri Nippon Symphony Orchestra, Tokyo)
 

Contact information

Secretariat of “THE 12th INTERNATIONAL OBOE COMPETITION OF JAPAN 2018 in Tokyo”
c/o Sony Music Foundation
Shin Togami
Address: SME-Rokubancho Bldg., 4-5 Rokubancho, Chiyoda-ku, Tokyo, 102-8353 Japan
Phone: +81-(0)3-3515-5261 (10:00 - 18:00 Japan time, on weekdays)
e-mail: smf@sonymusic.co.jp*
URL: http://oboec.jp/index_e
*Please inquire by e-mail when you contact us.

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Norsk Titanium Announces Strategic Investment from Rose Park Advisors’ Disruptive Innovation Fund20.11.2017 16:00Tiedote

Norsk Titanium, the metal additive manufacturing pioneer, today announced it has closed on a significant investment from Rose Park Advisors’ Disruptive Innovation Fund, known for its application of the theory of Disruptive Innovation® developed by co-founder Clayton Christensen. Terms of the investment were not released. “This strategic investment from Rose Park Advisors underscores the ability of Norsk Titanium’s Rapid Plasma Deposition™ (RPD™) technology to disrupt the metal manufacturing processes,” said Norsk Titanium Chairman of the Board John Andersen, Jr. “There are few people that are as widely respected by more business leaders than Dr. Christensen. We are humbled by his recognition of our technology and business model.” “Our strong relationships in commercial aerospace have allowed us to improve our processes and create a platform technology under the watchful eyes

Boehringer Ingelheim Makes Many of Its Best Molecules Openly Available to the Scientific Community Via opnMe.com To Unlock Their Full Potential20.11.2017 16:00Tiedote

Boehringer Ingelheim today announced the launch of opnME.com, a new platform offering free and open access to selected pre-clinical molecules for non-clinical investigation to scientists worldwide. Through opnME.com, molecules for some of the most relevant targets in biomedical research are shared, thereby creating possibilities for further independent and collaborative discovery as well as the identification of novel treatment approaches for patients. “Working together with scientists across the world, we can accelerate research in a wide range of biomedical research areas,“ said Clive R. Wood, PhD, Senior Corporate Vice President, Discovery Research at Boehringer Ingelheim. “This exciting new initiative further expands Boehringer Ingelheim’s global external innovation footprint and will help unlock the full potential of some of our most interesting compounds. By sharing these compoun

LivaNova Enters into Binding Letter of Intent to Sell its Cardiac Rhythm Management Business Franchise to MicroPort Scientific Corporation for $190 Million20.11.2017 11:43Tiedote

LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) and MicroPort Scientific Corporation (HK:00853) (“MicroPort”) today announced that the companies have entered into a binding Letter of Intent (“LOI”) for the sale of LivaNova’s Cardiac Rhythm Management (“CRM”) Business Franchise to MicroPort for $190 million in cash. The CRM Business Franchise develops, manufactures and markets products for the diagnosis, treatment and management of heart rhythm disorders and heart failures. CRM products include high-voltage defibrillators, cardiac resynchronization therapy devices and low-voltage pacemakers. The CRM Business Franchise generated approximately $249 million in net sales in fiscal year 2016 and has approximately 900 employees with operations chiefly in Clamart, France; Saluggia, Italy; and Santo Domingo, Dominican Republic. MicroPort is a leading medical device company, focused on innova

Chugai's Bispecific Antibody Emicizumab Meets Primary Endpoint in Phase lll Study20.11.2017 11:29Tiedote

Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the primary endpoint has been met for the global phase lll HAVEN 3 (NCT02847637) study evaluating emicizumab (ACE910) subcutaneous injection, once a week and once every two weeks, in patients with hemophilia A (12 years of age or older) without inhibitors to factor Vlll. A statistically significant reduction in the number of bleeds was confirmed in patients treated with emicizumab prophylaxis compared to those receiving no prophylactic treatment. The study also met a secondary endpoint that once-weekly emicizumab prophylaxis was superior to factor VIII prophylaxis, as demonstrated by a statistically significant and clinically meaningful reduction in treated bleeds in an intra-patient comparison of patients receiving emicizumab prophylaxis compared to their prior factor VIII prophylaxis. The most common adverse events with em

Synteract Thought Leaders to Speak & Exhibit at Partnerships in Clinical Trials Europe in Amsterdam20.11.2017 11:00Tiedote

(Booth #17) – Thought leaders from Synteract, a full-service, international contract research organization (CRO), will exhibit and present at Partnerships in Clinical Trials Europe (PCT), November 28-29, Amsterdam, Netherlands. With awareness of the shifting CRO landscape and the complexity this represents to biopharma companies as they make critical outsourcing decisions, Synteract invites attendees to “Pause to rethink what matters most from your CRO.” Vice President, Global Medical and Regulatory Affairs at Synteract, Dr. Martine Dehlinger-Kremer, will speak on “The EU Clinical Trials Regulation: Are you prepared for its implementation?” at the event on Tuesday, November 28 at noon. She will address how evolving industry needs are driving momentum towards implementation of a new regulation governing clinical trials, the expected impact on sponsors and necessary steps toward p

Fiorano Launches PSD2 Solution for Banks for Seamless Regulatory Compliance20.11.2017 11:00Tiedote

Fiorano Software, a proven global leader in Integration Middleware and API Management, today announced the launch of Fiorano PSD2, a platform solution enabling banks to comply with the European Union’s Revised Payment Service Directive (PSD2) regulations. Fiorano’s end-to-end PSD2 solution is built on the industry's leading banking Integration and API Management infrastructure serving as an onramp for future eDigital Banking initiatives. Banks across Europe need to be PSD2 compliant by January 2018. They are also facing severe competition from FinTechs to improve online payments, customer engagement experiences and making cross-border payments safer. “By building on PSD2 as a solution on top of a tightly integrated API Management and ESB platform, Fiorano masks complex technical details, dramatically simplifies the time and effort for compliance,” said Mr. Atul Saini, CEO of Fio

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme